InMed Pharmaceuticals Inc. (INM) · Nov 19, 2026 · Auditor change

Mentari Therapeutics auditor change puts Deloitte in after InMed merger

Deloitte engaged — Deloitte appointed for fiscal year ending December 31, 2026

Mentari Therapeutics changed auditors after its InMed reverse merger, appointing Deloitte while reporting no disagreements or reportable events.

Mentari is now a clinical-stage migraine-prevention biotech built around MT-001 and MT-002, following its reverse merger with InMed and a previously announced $490 million financing intended to fund development into multiple 2027 data catalysts.

This is post-merger accounting cleanup, not a change in the operating story. The company dismissed CBIZ, which audited legacy InMed, and Ernst & Young, which audited legacy Mentari, then appointed Deloitte for the December 31, 2026 year-end. The filing says there were no disagreements or “reportable events” involving either outgoing auditor. 〔0〕 〔1〕

The going-concern language is inherited, not a fresh deterioration. Both legacy audit reports contained explanatory paragraphs about substantial doubt over continuing as a going concern, but that disclosure was already attached to the pre-merger entities; this filing does not add a new financial warning or revise the post-merger funding position. The practical test is Deloitte’s first audit of the combined company, whose historical financial statements will be based on Mentari as the accounting acquirer.

Bottom line: The filing formalizes the auditor transition required by the reverse merger but does not materially change the migraine-development story or introduce a new accounting problem. It is routine infrastructure, not a substantive business signal.

What to watch next

First audited December 31, 2026 annual report

Original filing on SEC EDGAR

More InMed Pharmaceuticals Inc. news

Mentari Therapeutics auditor change puts Deloitte in after InMed merger | INM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.